Street Calls of the Week
Investing.com - TD Cowen has reiterated its Buy rating and $115.00 price target on Boston Scientific (NYSE:BSX) following an analyst visit to the company’s headquarters. The medical device giant, currently valued at $144 billion, enjoys a strong "GREAT" financial health score according to InvestingPro analysis.
The firm indicated that the visit reinforced its conviction in Boston Scientific’s outlook, which it had developed during the company’s investor day last week. This optimism aligns with the broader Wall Street consensus, as the company has achieved impressive revenue growth of 21.4% over the last twelve months.
TD Cowen noted that discussions during the visit covered significant ground in pulsed field ablation (PFA) technology, with the firm receiving responses suggesting Boston Scientific maintains a "very compelling" outlook despite facing new competition in the space.
The research note highlighted comments from CEO Mike Mahoney, who provided "thoughtful replies" to various growth questions that emphasized his focus on category leadership as a strategy for contracting success.
Boston Scientific remains TD Cowen’s top pick in the sector, with analyst Joshua Jennings expressing renewed conviction in the company’s prospects following the headquarters visit.
In other recent news, Boston Scientific has been the subject of various analyst assessments following its Investor Day event. The company has reiterated its long-range plan, projecting over 10% organic sales growth and double-digit EPS growth from 2026 to 2028. RBC Capital has maintained an Outperform rating with a $125.00 price target, while TD Cowen also reiterated a Buy rating and set a $115.00 price target, reflecting confidence in the company’s growth prospects. Stifel echoed this sentiment, maintaining a Buy rating and a $125.00 price target, citing Boston Scientific’s innovation and strong management.
However, Erste Group downgraded the stock from Buy to Hold, pointing to its high price-to-earnings ratio as a limiting factor for stock price growth. Piper Sandler, on the other hand, maintained an Overweight rating with a $115.00 price target, despite concerns about potential deceleration in the Pulsed Field Ablation business. These mixed assessments underscore the varied outlooks among analysts regarding Boston Scientific’s future performance. These developments provide a comprehensive view of the company’s current standing in the eyes of financial analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.